JP Morgan Chase’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-45,900
Closed -$445K 6736
2022
Q3
$445K Buy
+45,900
New +$608K ﹤0.01% 4534

Other funds holding HCAT

JP Morgan Chase's HCAT Position: Q1 2026 in Review

JP Morgan Chase reduced its Health Catalyst (HCAT) stake by 9.9% in Q1 2026, selling an estimated $141K and leaving 677,949 shares worth $800K. The position accounts for ﹤0.01% of the portfolio, ranked #4735.

JP Morgan Chase first reported a position in HCAT in Q3 2019 and has held it in 27 quarters since. The position peaked at $26.3M in Q2 2023. 130 funds tracked by Wall St. Rank hold HCAT as of Q1 2026.

  • JP Morgan Chase held 677,949 shares of Health Catalyst worth $800K as of Q1 2026.
  • JP Morgan Chase sold 74,857 Health Catalyst shares in Q1 2026, an estimated $141K.
  • Health Catalyst made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4735 holding.
  • JP Morgan Chase first reported a position in Health Catalyst in Q3 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Health Catalyst position peaked at $26.3M in Q2 2023.
  • 130 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.